Targeting the transcription factor Myb by small-molecule inhibitors
Research output: Contribution to journal › Article
Colleges, School and Institutes
The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.
|Early online date||23 Dec 2016|
|Publication status||Published - 1 Mar 2017|